Report
Biotechnology: Cassiopea reports strong phase III results in Acne
BiotechnologyCassiopea reports strong phase III results in Acne
Cassiopea SpA (SIX: SKIN), is a late clinical stage dermatology product development company currently valued at circa CHF302m (CHF30.20 per share). Today the company reported positive phase III results for its lead programme, Winlevi, in acne vulgaris. The company has completed two international phase III clinical trials and with these results we believe it will be in a position to file an NDA for Winlevi in Q1 2019 and progress its preparations for the commercialisation of the product in the USA.
Provider
Bryan Garnier
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Gary Waanders
Other Reports from Bryan Garnier
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.